These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 23381589)
1. Drug companies lobby against generic versions of biologics. Tucker ME BMJ; 2013 Feb; 346():f740. PubMed ID: 23381589 [No Abstract] [Full Text] [Related]
2. Insights of biosimilars through SWOT analysis. Patel MM; Shah PJ; Patel BM Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903 [No Abstract] [Full Text] [Related]
3. On safety margin for drug interchangeability. Zheng J; Chow SC; Song F J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675 [TBL] [Abstract][Full Text] [Related]
4. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics. Wright EE; Blevins TC; Reed B; Pollom RD J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404 [TBL] [Abstract][Full Text] [Related]
5. Strategic considerations under the Biologics Price Competition and Innovation Act. Marquardt JL; Auten SR Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693 [TBL] [Abstract][Full Text] [Related]
6. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines. Heller WM Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792 [No Abstract] [Full Text] [Related]
8. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology . Harenberg J; Kalodiki E; Walenga JM; Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973 [No Abstract] [Full Text] [Related]
9. Bioequivalence/bioavailability retention samples. Ransom C Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218 [No Abstract] [Full Text] [Related]
10. Biosimilars take center stage. Adams KT Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533 [No Abstract] [Full Text] [Related]
11. Competition in the Age of Biosimilars. Chandra A; Vanderpuye-Orgle J JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179 [No Abstract] [Full Text] [Related]
12. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
13. The other path for follow-ons. Nat Biotechnol; 2008 Jul; 26(7):715. PubMed ID: 18612272 [TBL] [Abstract][Full Text] [Related]
14. Impurities in generic pharmaceutical development. Kovaleski J; Kraut B; Mattiuz A; Giangiulio M; Brobst G; Cagno W; Kulkarni P; Rauch T Adv Drug Deliv Rev; 2007 Jan; 59(1):56-63. PubMed ID: 17196702 [TBL] [Abstract][Full Text] [Related]
16. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
17. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response. Grice S N Z Bioeth J; 2003 Oct; 4(3):22-4. PubMed ID: 15597479 [No Abstract] [Full Text] [Related]
19. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009. Carver KH; Elikan J; Lietzan E Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247 [TBL] [Abstract][Full Text] [Related]
20. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related] [Next] [New Search]